What does FARMAKS do?

FARMAKS is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 4 April 2000, 1 establishment.

What is the address of FARMAKS?

The registered office of FARMAKS is located at Dorpsstraat 110, 8300 Knokke-Heist.

Is FARMAKS still active?

Yes. According to the CBE (16 September 2026) FARMAKS is active, legal situation “Normale toestand”, started on 4 April 2000.

Is FARMAKS registered on Peppol?

Yes, FARMAKS is registered on the Peppol network with ID 0208:0471595984.

What is the enterprise number of FARMAKS?

The enterprise number of FARMAKS is BE0471595984.

When was FARMAKS founded?

FARMAKS was founded on 4 April 2000.

Who are the directors of FARMAKS?

According to the 2025 annual accounts, the directors of FARMAKS are: Kurt Lefever, Sofie De Cloedt.

Is FARMAKS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 4 April 2000; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did FARMAKS make in 2025?

FARMAKS posted a profit after taxes of € 375,394 in financial year 2025.

What is the revenue of FARMAKS?

As a small company, FARMAKS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 282,422.

FARMAKS (Private Limited) - Knokke-Heist - BE0471595984

Dossier FARMAKS, printed on 16 September 2026 from databakkes.be/en/0471595984/farmaks. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

FARMAKS from Knokke-Heist, company number BE0471595984, closed financial year 2025 with a result of € 375,394 after tax. For that financial year FARMAKS recorded a gross margin of € 282,422 and equity of € 1.9 million. Compared with financial year 2024, the result moved from € 191,354 to € 375,394. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 29, 2026.

What it is worth Growing

€ 1.9 million

▲ 8% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 375,394

▲ 96% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 570,811

▲ 12% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 236,709 paid out

63 % of the profit went to the shareholders, the rest stayed in the company.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 140,705

▼ 40% vs 2024

€ 93,572 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 3,300

▲ 52% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 63,718

▼ 10% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 299,652 Gross margin 2022: € 299,652 First fiscal year in the series	€ 302,941 Gross margin 2023: € 302,941 ▲ 1% vs 2022 (€ 299,652) Favourable step	€ 280,108 Gross margin 2024: € 280,108 ▼ 8% vs 2023 (€ 302,941) Unfavourable step	€ 282,422 Gross margin 2025: € 282,422 ▲ 1% vs 2024 (€ 280,108) Favourable step	▲ 1%
Profit after taxes	€ 472,251 Profit after taxes 2022: € 472,251 First fiscal year in the series	€ 658,107 Profit after taxes 2023: € 658,107 ▲ 39% vs 2022 (€ 472,251) Favourable step	€ 191,354 Profit after taxes 2024: € 191,354 ▼ 71% vs 2023 (€ 658,107) Unfavourable step	€ 375,394 Profit after taxes 2025: € 375,394 ▲ 96% vs 2024 (€ 191,354) Favourable step	▲ 96%
Equity	€ 1,658,419 Equity 2022: € 1,658,419 First fiscal year in the series	€ 2,088,960 Equity 2023: € 2,088,960 ▲ 26% vs 2022 (€ 1,658,419) Favourable step	€ 1,750,314 Equity 2024: € 1,750,314 ▼ 16% vs 2023 (€ 2,088,960) Unfavourable step	€ 1,888,999 Equity 2025: € 1,888,999 ▲ 8% vs 2024 (€ 1,750,314) Favourable step	▲ 8%
Total debts	€ 649,207 Total debts 2022: € 649,207 First fiscal year in the series	€ 766,350 Total debts 2023: € 766,350 ▲ 18% vs 2022 (€ 649,207) Unfavourable step	€ 927,826 Total debts 2024: € 927,826 ▲ 21% vs 2023 (€ 766,350) Unfavourable step	€ 1,051,018 Total debts 2025: € 1,051,018 ▲ 13% vs 2024 (€ 927,826) Unfavourable step	▲ 13%
Cash	€ 357,248 Cash 2022: € 357,248 First fiscal year in the series	€ 146,354 Cash 2023: € 146,354 ▼ 59% vs 2022 (€ 357,248) Unfavourable step	€ 510,582 Cash 2024: € 510,582 ▲ 249% vs 2023 (€ 146,354) Favourable step	€ 570,811 Cash 2025: € 570,811 ▲ 12% vs 2024 (€ 510,582) Favourable step	▲ 12%
Retained profit	€ 1,412,519 Retained profit 2022: € 1,412,519 First fiscal year in the series	€ 2,068,960 Retained profit 2023: € 2,068,960 ▲ 46% vs 2022 (€ 1,412,519) Favourable step	€ 1,730,314 Retained profit 2024: € 1,730,314 ▼ 16% vs 2023 (€ 2,068,960) Unfavourable step	€ 1,868,999 Retained profit 2025: € 1,868,999 ▲ 8% vs 2024 (€ 1,730,314) Favourable step	▲ 8%
Dividend	€ 1,600 Dividend 2022: € 1,600 First fiscal year in the series	€ 1,666 Dividend 2023: € 1,666 ▲ 4% vs 2022 (€ 1,600) Unchanged	€ 530,000 Dividend 2024: € 530,000 ▲ € 528,334 vs 2023 (€ 1,666) Unchanged	€ 236,709 Dividend 2025: € 236,709 ▼ 55% vs 2024 (€ 530,000) Unchanged	▼ 55%
Bank debt	€ 415,965 Bank debt 2022: € 415,965 First fiscal year in the series	€ 325,112 Bank debt 2023: € 325,112 ▼ 22% vs 2022 (€ 415,965) Favourable step	€ 233,361 Bank debt 2024: € 233,361 ▼ 28% vs 2023 (€ 325,112) Favourable step	€ 140,705 Bank debt 2025: € 140,705 ▼ 40% vs 2024 (€ 233,361) Favourable step	▼ 40%
Balance sheet total	€ 2,307,627 Balance sheet total 2022: € 2,307,627 First fiscal year in the series	€ 2,855,310 Balance sheet total 2023: € 2,855,310 ▲ 24% vs 2022 (€ 2,307,627) Unchanged	€ 2,678,140 Balance sheet total 2024: € 2,678,140 ▼ 6% vs 2023 (€ 2,855,310) Unchanged	€ 2,940,017 Balance sheet total 2025: € 2,940,017 ▲ 10% vs 2024 (€ 2,678,140) Unchanged	▲ 10%

Key figures of FARMAKS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to FARMAKS?

What happened at FARMAKS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 29, 2026 New annual accounts for financial year 2025: profit of € 375,394 (▲ 96% vs 2024). filed late Source: NBB ↗
2023 Kurt Lefever became a director. NBB
2023 Sofie De Cloedt became a director. NBB
Jun 13, 2000 New establishment in Knokke-Heist. KBO
Apr 4, 2000 Start of the company according to the CBE. KBO

In short

From € 472,251 profit in 2022 to € 375,394 profit in 2025.

Paid € 435,246 in corporate taxes since 2022.

Best year ever: 2023, with € 658,107 profit.

Paid out € 769,975 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at FARMAKS? We notify you, reason included.

Follow FARMAKS

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Kurt Lefever

Sofie De Cloedt

FARMAKS

Apotheek Kalvekeetdijk 99.2%

Apotheek Lefever - De Cloedt 98.7%

Behind FARMAKS are Kurt Lefever and Sofie De Cloedt. It owns 99.2% of Apotheek Kalvekeetdijk and 98.7% of Apotheek Lefever - De Cloedt itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Kurt Lefever

Director

Also active at: APOTHEEK LEFEVER - DE CLOEDT, APOTHEEK KALVEKEETDIJK

since 2023

Sofie De Cloedt

Director

Also active at: APOTHEEK LEFEVER - DE CLOEDT, APOTHEEK KALVEKEETDIJK

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Dorpsstraat 110

8300 Knokke-Heist

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

APOTHEEK LEFEVER - DE CLOEDT same network

€ 199,947 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0471.595.984

VAT number

BE 0471.595.984

Registered office

Dorpsstraat 110, 8300 Knokke-Heist

Names & denominations

FARMAKS

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

4 April 2000

Peppol

Active · Active since 29 Sept 2025

Activities · NACE

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

FARMAKS

Financials

What happened to FARMAKS?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions